EVERSANA
A Chicago company, owned by private equity since 2018, that runs drug launches, marketing and patient services for 670+ drugmakers. It is now betting on AI-run marketing and a drug-pricing platform.
EVERSANA company overview, Jun 2026- Revenue
- ~$1B+ 2025 revenue, the company's own rounded figure; no audited numbers are published.
- Owner
- Water Street healthcare private equity owner since 2018, first alongside JLL Partners; no priced rounds or valuation.
- Clients
- 670+ clients and about 6,000 employees, per the company; it says it works with all top biopharma companies.
- AI
- AI Agency a marketing agency it calls 80% AI-powered, built on Google Cloud's Gemini models.
- Watch
- Exit timing owned by the same buyout firm for over eight years, with a new CFO who has run public-company finances.
- Liquidity
- None found no tender offer or staff share sale reported; equity value depends on a sale or listing.
- Hiring
- 174 → 184 remote listings since Oct 10.
Paid by drugmakers to get medicines to patients.
EVERSANA sells commercial services to pharma and biotech: advisory, pricing and market access, marketing agencies (EVERSANA INTOUCH), field sales reps, patient hubs and copay programs, specialty pharmacy, and 3PL distribution. Its COMPLETE model runs a whole launch for a client; it does not split revenue by line publicly.
EVERSANA company overview, Jun 2026- 1One partner for the whole launchIt sells pricing, access, agency, field reps, patient services and distribution under one roof, and says it has 30+ complete partnerships.EVERSANA company overview, Jun 2026
- 2Already inside most of pharma670+ clients, including all top biopharma companies by its own count.EVERSANA company overview, Jun 2026
- 3A payer and pharmacy network from WaltzThe Waltz merger added a URAC-accredited specialty pharmacy network and direct-to-payer tools that connect insurers, employers and PBMs.HIT Consultant, Aug 26, 2025
- McKesson$116Blisted, Oct 30 close
- Cencora$63.1Blisted, Oct 30 close
- IQVIA$44.1Blisted, Oct 30 close
- Omnicom$22.2Blisted, Oct 30 close
- Precision Medicine Group$2.25Bprivate, Aug 25
Private values are the last reported round; they can be stale. Listed values are market value. Bars start at zero.
Every round, and what its terms give away.
EVERSANA is private, so there is no share price. What its investors paid, and on what terms, is the closest thing to one.
- $1.00B
- annual revenue, as of Dec 31
- 6,000
- employees, as reported
Not disclosed.
EVERSANA company overview, Jun 2026 ("~$1B+ 2025 revenue", "~6,000 employees")- Aug 26Merger with Waltz HealthLed by Water Street-backed EVERSANATerms not disclosed. Coverage called the combined company $6 billion; that is not a priced valuation.MedCity News, Aug 27, 2025
- Apr 27Waltz Health Series A (pre-merger)$35MLed by GVRaised by Waltz before it merged into EVERSANA; Define, Echo Health Ventures and others joined.FinSMEs, Apr 27, 2022
- Feb 20Private equity buyoutLed by Water Street Healthcare Partners and JLL PartnersBought Dohmen Life Science Services; six firms were merged into EVERSANA by Oct 2018. Price not disclosed.BizTimes Milwaukee, Feb 20, 2018
- Down or flat round?No priced round or valuation has been published. EVERSANA is owned by a buyout firm, so its value is set privately.Levin Associates, Aug 28, 2025Open
- How long the owner has held itWater Street and JLL bought the first piece in early 2018, over eight years ago. Long holds usually end in a sale or recapitalization.BizTimes Milwaukee, Feb 20, 2018Flag
- Debt and unusual termsBuyout companies usually carry loans; EVERSANA's debt size, terms and ratings were not found in public sources we could open.Levin Associates, Aug 28, 2025Open
- Who controls itWater Street is named as owner in 2025 coverage. JLL Partners' current stake was not confirmed.Levin Associates, Aug 28, 2025Open
- Can staff sell shares?No tender offer or staff secondary sale found. Equity, if offered, likely pays out only on an exit.Levin Associates, Aug 28, 2025Open
- Layoffs in the last 12 months?No WARN notice or announced cuts found in search; state databases not checked one by one. The Asia-Pacific and Middle East advisory team moved to Trinity in Nov 2025.Pulse 2.0, Nov 5, 2025Open
Clear: checked, nothing found. Flag: found, with the source. Open: could not be checked.
What the record says, and what we think it means.
The fact is the source's. The read, in italics, is ours.
- 01Neutral
Merged with drug-pricing startup Waltz Health.
MedCity News, Aug 27, 2025Announced Aug 26, 2025; terms not disclosed. Waltz connects insurers, employers, PBMs and pharmacies for specialty drugs.
It moves EVERSANA from serving drugmakers toward the payer side, where drug pricing and PBM rules are politically hot. A bigger bet, with more regulatory exposure.
- 02Neutral
Former OptumRx chief became CEO.
MedCity News, Aug 27, 2025Waltz co-founder Mark Thierer, EVERSANA's chairman for eight years and once CEO of OptumRx, took over; former CEO Jim Lang moved to the board.
A pharmacy-benefits operator now runs the company, matching the payer push.
- 03Neutral
New CFO with public-company experience.
pharmaphorum (EVERSANA-owned), Oct 15, 2026Stuart Diamond joined as CFO in Aug or Sep 2026; he has been CFO of three public companies and most recently of WPP Media.
A common hire ahead of a sale or listing, though nothing has been announced.
- 04Watch
Marketing agency rebuilt as 80% AI.
pharmaphorum (EVERSANA-owned), Aug 4, 2025Launched Aug 2025 on Google Cloud: AI agents do strategy, content, omnichannel and media work, with a lean human team per brand.
Good for margins, but it implies fewer agency roles over time. No job cuts were announced with it.
- 05Good
First big pharma client went all-in on the AI platform.
pharmaphorum (EVERSANA-owned), Aug 25, 2026Lundbeck expanded EVERSANA's AI Agency across its US marketing, medical communications, market access and media in Aug 2026.
A named reference client for a new product. Contract value was not disclosed.
- 06Neutral
Bought a UK health-economics AI firm.
Pharmaceutical Commerce, Oct 28, 2026Acquired London-based Estima Scientific on Oct 28, 2026; terms not disclosed.
Adds AI tools for the evidence payers demand. Small, but a sign the owner is still funding add-ons.
- 07Watch
Sold its Asia-Pacific and Middle East advisory arm.
Pulse 2.0, Nov 5, 2025Trinity Life Sciences took over the regional advisory teams (Singapore, Tokyo, Mumbai, Shanghai, Sydney, Dubai) in Nov 2025; price not disclosed.
Trimming non-core pieces is typical before a sale. The two firms will keep working together there.
- 08Neutral
Owns a pharma trade publication.
pharmaphorum (EVERSANA-owned), Aug 25, 2026pharmaphorum describes itself as editorially independent and owned by EVERSANA.
Much of the trade coverage of EVERSANA comes from its own outlet, so weigh it accordingly.
What the hiring data says.
We save every company's roles, pay by team and level, AI share and churn every day, so each month this page can say more. Sparklines use their own scale.
Can AI agents do business with EVERSANA?
We checked the agent payment programs, developer docs and site rules an AI assistant would meet.
Builds agents, hard for agents to reach. An AI agency on Gemini and a Veeva AI partnership, but a bot wall blocks automated readers.
Still Remote read- YesRuns its own AI agentsIts AI Agency uses Gemini models on Google's Vertex AI, with agents for strategy, content, media and MLR review.pharmaphorum (EVERSANA-owned), Aug 4, 2025
- YesListed in a pharma AI partner programJoined Veeva's AI Partner Program in Apr 2025, building apps that plug into Veeva Vault and PromoMats.pharmaphorum (EVERSANA-owned), Apr 1, 2025
- YesAn llms.txt filePresent on the main site, auto-generated by an SEO plugin: a list of posts and the sitemap, no product or developer docs.checked Oct 31, 2026
- Yesrobots.txt rules for AI botsNo AI crawlers named or blocked. Only MJ12bot, SleepBot and Barkrowler are banned; search and admin paths closed to all.checked Oct 31, 2026
- MixedCan automated tools read the site?Home, news and article pages returned a Cloudflare 'Sorry, you have been blocked' page to plain automated requests; robots.txt and llms.txt loaded.checked Oct 31, 2026
- Not foundAn MCP server or agent protocolNo MCP server, public API docs or agent-commerce listing found; it sells services to drugmakers, not self-serve products.checked Oct 31, 2026
Where EVERSANA puts AI to work.
- 1AI does most of the agency workIts AI Agency is described as 80% AI-powered, with a lean brand team and subject experts guiding strategy and creative.pharmaphorum (EVERSANA-owned), Aug 4, 2025
- 2Spreading AI past marketingIn Aug 2026 it extended the platform to medical affairs, market research, MLR review and field sales, with market access and patient services next.BioXconomy, Aug 21, 2026
- 3Still early, by the CEO's accountMark Thierer says AI's biggest impact is automating complex processes at scale, and the industry has "a ton of work to do to move past pilots."Pharmaceutical Commerce, Oct 28, 2026
More listings than on Sep 7, led by sales.
The signals, and which way they push.
- TailwindDrugmakers going direct to patients and payers.
EVERSANA helped Eli Lilly build LillyDirect and plans a similar model offered to payers inside funded benefit plans.
- TailwindPharma clients are buying AI-run commercialization.
Lundbeck expanded the AI Agency across its US commercial organization in Aug 2026.
- HeadwindBig distributors are buying rivals.
McKesson agreed to buy Precision Medicine Group, a commercialization services rival, for about $2.25B in Aug 2026.
- HeadwindAI shrinks the agency labor model.
An 80% AI-powered agency needs fewer people per brand, which pressures agency headcount and pricing industry-wide.
- HeadwindAn aging buyout.
Water Street has owned it since 2018 and closed a new $1.9B fund in May 2026; older holdings are usually the ones sold.
Where EVERSANA ends up, if we had to bet.
Our calls, not facts. Each one is tied to something that already happened, so you can judge the reasoning.
- 1
EVERSANA is sold or recapitalized by its private equity owner by 2031.
Likely 72%M&AWater Street and JLL first bought in 2018, and a public-company CFO joined in 2026. Selling a regional unit and adding small deals fits a business being readied for an exit.
pharmaphorum (EVERSANA-owned), Oct 15, 2026; BizTimes, Feb 2018 - 2
EVERSANA is a listed company by 2033.
Long shot 16%IPONo filing or plan has been reported. Services firms like it more often go to strategic buyers, as McKesson's Precision deal shows.
Pharmaceutical Executive, Aug 25, 2026 - 3
A drug distributor or health giant ends up owning EVERSANA.
Coin flip 50%CompetitionMcKesson paid about $2.25B for rival Precision Medicine Group in 2026. EVERSANA's 3PL, specialty pharmacy and hub services overlap with what distributors want.
Pharmaceutical Executive, Aug 25, 2026 - 4
The Waltz direct-to-payer business becomes a major revenue line by 2033.
Coin flip 50%ProductsThe CEO built it and the merger was framed around specialty drugs and GLP-1s. PBM rules and payer adoption could slow it.
MedCity News, Aug 27, 2025 - 5
Most of EVERSANA's agency and medical content work is produced by AI agents by 2031.
Likely 72%AIIt already calls its agency 80% AI and is extending agents into medical affairs and research. The CEO says moving past pilots is the remaining work.
BioXconomy, Aug 21, 2026
Read by the Still Remote research agent on November 1, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.